对皮肤癌患者进行局部免疫治疗：系统回顾

IF 9.6 1区医学 Q1 ONCOLOGY

Cancer treatment reviews Pub Date : 2024-10-28 DOI:10.1016/j.ctrv.2024.102848

J.C. Janssen , B. van Dijk , L.L. Hoeijmakers , D.J. Grünhagen , W.M. Bramer , C. Verhoef , T.D. de Gruijl , C.U. Blank , A.A.M. van der Veldt

{"title":"对皮肤癌患者进行局部免疫治疗：系统回顾","authors":"J.C. Janssen , B. van Dijk , L.L. Hoeijmakers , D.J. Grünhagen , W.M. Bramer , C. Verhoef , T.D. de Gruijl , C.U. Blank , A.A.M. van der Veldt","doi":"10.1016/j.ctrv.2024.102848","DOIUrl":null,"url":null,"abstract":"<div><div>Since the introduction of immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 receptors, survival has improved significantly for patients with irresectable and metastatic skin cancer, including cutaneous squamous cell cancer and melanoma. However, systemic administration of these drugs is associated with immune related adverse events (irAEs), which can be severe, irreversible and even fatal. To reduce the risk of irAEs associated with systemic exposure to immunotherapeutic drugs, local administration of low doses could be considered. This systematic review provides an overview of early phase clinical trials with drugs that are currently under investigation for intratumoral administration in patients with melanoma and non-melanoma skin cancer.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"131 ","pages":"Article 102848"},"PeriodicalIF":9.6000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Local administration of immunotherapy for patients with skin cancer: A systematic review\",\"authors\":\"J.C. Janssen , B. van Dijk , L.L. Hoeijmakers , D.J. Grünhagen , W.M. Bramer , C. Verhoef , T.D. de Gruijl , C.U. Blank , A.A.M. van der Veldt\",\"doi\":\"10.1016/j.ctrv.2024.102848\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Since the introduction of immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 receptors, survival has improved significantly for patients with irresectable and metastatic skin cancer, including cutaneous squamous cell cancer and melanoma. However, systemic administration of these drugs is associated with immune related adverse events (irAEs), which can be severe, irreversible and even fatal. To reduce the risk of irAEs associated with systemic exposure to immunotherapeutic drugs, local administration of low doses could be considered. This systematic review provides an overview of early phase clinical trials with drugs that are currently under investigation for intratumoral administration in patients with melanoma and non-melanoma skin cancer.</div></div>\",\"PeriodicalId\":9537,\"journal\":{\"name\":\"Cancer treatment reviews\",\"volume\":\"131 \",\"pages\":\"Article 102848\"},\"PeriodicalIF\":9.6000,\"publicationDate\":\"2024-10-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer treatment reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0305737224001774\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0305737224001774","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

自以 PD-1 和 CTLA-4 受体为靶点的免疫检查点抑制剂（ICIs）问世以来，包括皮肤鳞状细胞癌和黑色素瘤在内的不可切除和转移性皮肤癌患者的生存率得到了显著提高。然而，这些药物的全身用药与免疫相关不良事件（irAEs）有关，这些不良事件可能是严重的、不可逆的，甚至是致命的。为了降低全身暴露于免疫治疗药物所带来的irAEs风险，可以考虑小剂量局部用药。本系统综述概述了目前正在研究的用于黑色素瘤和非黑色素瘤皮肤癌患者瘤内给药的早期临床试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Local administration of immunotherapy for patients with skin cancer: A systematic review

Since the introduction of immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 receptors, survival has improved significantly for patients with irresectable and metastatic skin cancer, including cutaneous squamous cell cancer and melanoma. However, systemic administration of these drugs is associated with immune related adverse events (irAEs), which can be severe, irreversible and even fatal. To reduce the risk of irAEs associated with systemic exposure to immunotherapeutic drugs, local administration of low doses could be considered. This systematic review provides an overview of early phase clinical trials with drugs that are currently under investigation for intratumoral administration in patients with melanoma and non-melanoma skin cancer.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer treatment reviews 医学-肿瘤学

CiteScore

21.40

自引率

0.80%

发文量

109

审稿时长

13 days

期刊介绍： Cancer Treatment Reviews Journal Overview: International journal focused on developments in cancer treatment research Publishes state-of-the-art, authoritative reviews to keep clinicians and researchers informed Regular Sections in Each Issue: Comments on Controversy Tumor Reviews Anti-tumor Treatments New Drugs Complications of Treatment General and Supportive Care Laboratory/Clinic Interface Submission and Editorial System: Online submission and editorial system for Cancer Treatment Reviews